Alamar Biosciences Sets IPO at 9.4 Million Shares Priced at $15-$17 Each

Dow Jones

04/16

By Colin Kellaher

Alamar Biosciences on Thursday said it plans to sell nearly 9.4 million shares at between $15 and $17 apiece in its initial public offering.

At the $16 midpoint of that range, the Fremont, Calif., proteomics company said it expects net proceeds of about $133.2 million, or roughly $154.1 million if the underwriters exercise an option to buy an additional 1.41 million shares.

Alamar said it would have about 66.3 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization of roughly $1.06 billion at the $16-a-share pricing midpoint.

The company said it has applied to list its shares on the Nasdaq Global Select Market under the symbol ALMR.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 16, 2026 10:41 ET (14:41 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2627211129"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627211129\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627211129?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 22:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627211129","market":"nz","top_or_hot":-1,"title":"Alamar Biosciences Sets IPO at 9.4 Million Shares Priced at $15-$17 Each","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Alamar Biosciences on Thursday said it plans to sell nearly 9.4 million shares at between $15 and $17 apiece in its initial public offering. \n</p>\n<p>\n  At the $16 midpoint of that range, the Fremont, Calif., proteomics company  said it expects net proceeds of about $133.2 million, or roughly $154.1 million if the underwriters exercise an option to buy an additional 1.41 million shares. \n</p>\n<p>\n  Alamar said it would have about 66.3 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization of roughly $1.06 billion at the $16-a-share pricing midpoint. \n</p>\n<p>\n  The company said it has applied to list its shares on the Nasdaq Global Select Market under the symbol ALMR. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2026 10:41 ET (14:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alamar Biosciences Sets IPO at 9.4 Million Shares Priced at $15-$17 Each</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlamar Biosciences Sets IPO at 9.4 Million Shares Priced at $15-$17 Each\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-16 22:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Alamar Biosciences on Thursday said it plans to sell nearly 9.4 million shares at between $15 and $17 apiece in its initial public offering. \n</p>\n<p>\n  At the $16 midpoint of that range, the Fremont, Calif., proteomics company  said it expects net proceeds of about $133.2 million, or roughly $154.1 million if the underwriters exercise an option to buy an additional 1.41 million shares. \n</p>\n<p>\n  Alamar said it would have about 66.3 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization of roughly $1.06 billion at the $16-a-share pricing midpoint. \n</p>\n<p>\n  The company said it has applied to list its shares on the Nasdaq Global Select Market under the symbol ALMR. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2026 10:41 ET (14:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALMR","symbol_name":"Alamar Biosciences, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2627211129","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627211129","pubTimestamp":1776350460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Alamar Biosciences on Thursday said it plans to sell nearly 9.4 million shares at between $15 and $17 apiece in its initial public offering.At the $16 midpoint of that range, the Fremont, Calif., proteomics company  said it expects net proceeds of about $133.2 million, or roughly $154.1 million if the underwriters exercise an option to buy an additional 1.41 million shares.Alamar said it would have about 66.3 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization of roughly $1.06 billion at the $16-a-share pricing midpoint.The company said it has applied to list its shares on the Nasdaq Global Select Market under the symbol ALMR.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALMR":"Alamar Biosciences, Inc.","SPCX":"SPAC and New Issue ETF","IPOS":"Renaissance International IPO ETF"},"translate_title":"Alamar Biosciences将IPO规模定为940万股，每股定价为15-17美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALMR":1.5,"SPCX":1.5,"IPOS":1.5},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Alamar Biosciences on Thursday said it plans to sell nearly 9.4 million shares at between $15 and $17 apiece in its initial public offering. \n\n\n  At the $16 midpoint of that range, the Fremont, Calif., proteomics company  said it expects net proceeds of about $133.2 million, or roughly $154.1 million if the underwriters exercise an option to buy an additional 1.41 million shares. \n\n\n  Alamar said it would have about 66.3 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization of roughly $1.06 billion at the $16-a-share pricing midpoint. \n\n\n  The company said it has applied to list its shares on the Nasdaq Global Select Market under the symbol ALMR. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2026 10:41 ET (14:41 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}